Investigational drug · Phase 3
1.0% IP-001
Also called: IP-001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "1.0% IP-001"
First trial start
2022
Nov 29, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "1.0% IP-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer (CRC)
- Colon Cancer Liver Metastases
- Rectal Cancer
- Rectal Cancer With Liver Metastases
- Colorectal Liver Metastasis (CRLM)
- Metastatic Solid Tumor
- Colon Cancer
- Nonsmall Cell Lung Cancer
- Soft Tissue Sarcoma
Approved drugs for the same conditions: Small cell lung cancer · Colorectal cancer · Sarcoma · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "1.0% IP-001" as an intervention, largest first.
- Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver MetastasesPivotal-lookingNot yet recruiting
Immunophotonics, Inc.Industry
NCT07321847 · 717 participants (planned) · Start May 2026 · Primary completion Dec 2033
Drug: 1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water; 1.0% IP-001 for Injection, a 1 mg/mL solution of IP-001 in water. · For: Colorectal Cancer (CRC); Colon Cancer Liver Metastases; Rectal Cancer and 2 more
- Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation AlonePivotal-lookingRecruiting
Robert C. MartinAcademic, hospital or other
NCT06526338 · 315 participants (planned) · Start Jul 24, 2024 · Primary completion Dec 2029
Drug: 1.0% IP-001 for injection · For: Hepatocellular Carcinoma
Sites: Louisville, Kentucky
- Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STSActive, not recruiting
Immunophotonics, Inc.Industry
NCT05688280 · 42 participants · Start Nov 29, 2022 · Primary completion Feb 2025
Drug: 1.0% IP-001 for Injection · For: Metastatic Solid Tumor; Colon Cancer; Nonsmall Cell Lung Cancer and 1 more
Sites: Coral Gables, Florida; Louisville, Kentucky; Oklahoma City, Oklahoma · 16 sites in all
- Immunotherapy and Irreversible Electroporation (IRE) in the Treatment of Locally Advanced Pancreatic AdenocarcinomaNot yet recruiting
Robert C. MartinAcademic, hospital or other
NCT07930936 · 10 participants (planned) · Start Dec 1, 2026 · Primary completion Jan 1, 2030
Drug: 1.0% IP-001 for injection · For: Locally Advanced Pancreatic Adenocarcinoma
Sites: Louisville, Kentucky
Newest research
PubMed records naming it or its code names, newest first.
- Enhancing the Immunotherapeutic Effect by IP-001 and Irreversible Electroporation in Mouse Oligometastatic Models of Pancreatic Adenocarcinoma.
Li Y, Lam SSK, Gao Y, et al. · Ann Surg Oncol 2025
- N-Dihydrogalactochitosan Drives Conventional and Alternative Activations of STING to Synergize Type I IFN and IL-1β Productions for Antitumor Immunity.
Hoover AR, Liu K, Furrer C, et al. · Adv Funct Mater 2024
- Thermal ablation enhances immunotherapeutic effect of IP-001 on orthotopic liver cancer in a rat model.
Li Y, Lam SSK, Wong CF, et al. · Int J Hyperthermia 2024
- Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy.
Korbelik M, Hode T, Lam SSK, et al. · Cells 2021
- Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting.
Verona M, Rubagotti S, Croci S, et al. · Molecules 2021
Also in development for Colorectal Cancer (CRC)
- RMC-6291ElironrasibPhase 23 trials
Revolution Medicines, Inc. · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer
- GI-102Phase 22 trials
GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)
- BMS-986523Phase 21 trial
Bristol Myers Squibb · Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
- BPI-572270Phase 21 trial
Betta Pharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
- GEN1042Phase 21 trial
Genmab · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
- ImofinostatABT-301, MPT0E028Phase 21 trial
Anbogen Therapeutics, Inc. · Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC)
- JYP0015Phase 21 trial
Guangzhou JOYO Pharma Co., Ltd · Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC)
- SYS6062Phase 21 trial
CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Gastric Cancer (GC), Colorectal Cancer (CRC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.